Topical skin composition

Abstract

To provide an external composition for skin that has high storage stability and can prevent a foreign odor issuing from a phenolic antioxidant.SOLUTION: An external composition for skin contains (A) retinoid and (B) a phenolic antioxidant. The external composition for skin further contains (C1) 1,4-dioxacycloheptadecane-5,17-dione, (C2) benzyl salicylate, and at least one of (C3) 16-hydroxy-7-hexadecenoic acid lactone and (C4) 3a,6,6,9a-tetramethyl-dodecahydronaphtho[2,1-b]furan.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a retinoid-containing composition for external use on the skin. [Background technology]

[0002] Retinoic acid and retinol, which are types of retinoids, have the effect of improving skin wrinkles and have been incorporated into skin topical compositions. These compounds are known to act on epidermal keratinocytes to promote hyaluronic acid synthesis and increase moisture in the stratum corneum, thereby maintaining skin elasticity and improving wrinkles. Retinol in particular has a milder effect than retinoic acid and does not show strong side effects such as retinoid reactions, making it suitable for incorporation into cosmetic products. However, retinoids are unstable compounds and are easily oxidized by the effects of heat, light, oxygen, etc.

[0003] To prevent deterioration due to oxidation, antioxidants are added to compositions containing retinoids. In particular, phenol-based antioxidants such as tocopherol and dibutylhydroxytoluene (BHT) are used because they have a high antioxidant effect (Patent Document 1). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Patent Publication No. 2009-256268 Summary of the Invention [Problem to be solved by the invention]

[0005] However, these phenolic antioxidants have the problem of generating a sweet, unpleasant odor over time, which reduces the feel of the composition when used, and there is still a demand for a topical skin composition that can suppress the generation of unpleasant odors caused by phenolic antioxidants and has excellent storage stability. [Means for solving the problem]

[0006] In view of the above-mentioned problems, the present inventors have conducted intensive research and have surprisingly found that the above-mentioned problems can be solved by blending at least one of (C1) 1,4-dioxacycloheptadecane-5,17-dione, (C2) benzyl salicylate, and (C3) 16-hydroxy-7-hexadecenoic acid lactone or (C4) 3a,6,6,9a-tetramethyl-dodecahydronaphtho[2,1-b]furan with an external skin composition containing (A) a retinoid and (B) a phenolic antioxidant.

[0007] The present invention includes, for example, the inventions described below. Section 1. (A) retinoids, (B) a phenolic antioxidant, (C1) 1,4-dioxacycloheptadecane-5,17-dione, (C2) benzyl salicylate, and A composition for topical application to the skin containing at least one of (C3) 16-hydroxy-7-hexadecenoic acid lactone or (C4) 3a,6,6,9a-tetramethyl-dodecahydronaphtho[2,1-b]furan. Section 2. 2. The composition for external use on the skin according to claim 1, wherein (A) is retinol. Section 3. The composition for external application to skin according to claim 2, wherein (B) contains at least one of d-δ-tocopherol or dibutylhydroxytoluene. Section 4. The (C1) is 0.001 to 0.1 mass %, The (C2) is 0.0005 to 0.05 mass %, and 4. The composition for external use on the skin according to claim 1, comprising 0.0002 to 0.002 mass % of at least one of (C3) and (C4). Effect of the Invention

[0008] Provided is a composition for external use on the skin that is suppressed from generating unpleasant odors due to phenolic antioxidants and has excellent storage stability. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Each embodiment included in the present invention will be described in more detail below. The present invention preferably includes skin topical compositions, particularly skin topical compositions including (C1) 1,4-dioxacycloheptadecane-5,17-dione, (C2) benzyl salicylate, and (C3) 16-hydroxy-7-hexadecenoic acid lactone or (C4) 3a,6,6,9a-tetramethyl-dodecahydronaphtho[2,1-b]furan, but is not limited thereto, and the present invention includes all that is disclosed in this specification and that can be recognized by a person skilled in the art.

[0010] The retinoid (A) used in the present invention is not particularly limited as long as it can be used in a skin external composition, but examples thereof include retinol; retinol fatty acid esters such as retinol acetate, retinol propionate, retinol butyrate, retinol octyl acid, retinol laurate, retinol palmitate, retinol stearate, retinol myristate, retinol oleate, retinol linolenate, and retinol linoleate; retinol oxides such as retinal and retinoic acid; retinoic acid esters such as methyl retinoate, ethyl retinoate, retinol retinoate, and tocopherol retinoate (wherein tocopherol may be any of α, β, γ, and δ); and salts thereof, with retinol being particularly preferred. These retinoids can be formulated alone or in appropriate combination of two or more.

[0011] The retinoid (A) used in the present invention may be contained in an amount of about 0.01 to 1% by mass relative to the total amount of the composition. The upper or lower limit of the range of the content may be, for example, 0.02, 0.03, 0.04, 0.05, 0.08, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.6, 0.7, 0.8, or 0.9% by mass. For example, the range is more preferably 0.02 to 0.5% by mass, 0.025 to 0.25% by mass, or 0.03 to 0.1% by mass.

[0012] The (B) phenolic antioxidant used in the present invention is not particularly limited as long as it can be used in a skin topical composition, and examples thereof include monophenolic antioxidants, bisphenolic antioxidants, and polymeric phenolic antioxidants. Specifically, examples thereof include monophenolic antioxidants such as dibutyl hydroxytoluene, bisphenolic antioxidants such as 2,2'-methylene bis(4-methyl-6-tert-butylphenol), 2,2'-methylene bis(4-ethyl-6-tert-butylphenol), and 4,4'-butylidene bis(3-methyl-6-tert-butylphenol), and polymeric phenolic antioxidants such as tetrakis-[methylene-3-(3'-,5'-di-tert-butyl-4'-hydroxyphenyl)propionate]methane, and tocopherol, and d-δ-tocopherol and dibutyl hydroxytoluene are particularly preferred. In addition, these antioxidants can be used alone or in appropriate combination of two or more.

[0013] The phenolic antioxidant (B) used in the present invention can be contained in an amount of about 0.01 to 1% by mass based on the total amount of the composition. The upper or lower limit of the range of the content may be, for example, 0.02, 0.03, 0.04, 0.05, 0.08, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.6, 0.7, 0.8, or 0.9% by mass. For example, the range is more preferably 0.02 to 0.5% by mass, 0.025 to 0.25% by mass, or 0.03 to 0.1% by mass.

[0014] The (C1) used in the present invention can be contained in an amount of about 0.001 to 0.1% by mass based on the total amount of the composition. The upper or lower limit of the range of the content may be, for example, 0.002, 0.003, 0.004, 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, or 0.09% by mass. For example, the range is more preferably 0.005 to 0.075% by mass, or 0.01 to 0.05% by mass.

[0015] The (C2) used in the present invention can be contained in an amount of about 0.0005 to 0.05% by mass based on the total amount of the composition. The upper or lower limit of the range of the content may be, for example, 0.0008, 0.001, 0.002, 0.003, 0.004, 0.005, 0.01, 0.02, 0.03, or 0.04% by mass. For example, the range is more preferably 0.0075 to 0.025% by mass, or 0.001 to 0.01% by mass.

[0016] The composition of the present invention preferably contains at least one of (C3) and (C4). The total content of (C3) and (C4) may be about 0.0002 to 0.002 mass% based on the total amount of the composition. The upper or lower limit of the content range may be, for example, 0.0004, 0.0005, 0.0006, 0.0008, 0.001, 0.001, 0.0014, 0.0016, or 0.0018 mass%. For example, the range is more preferably 0.0004 to 0.0016 mass%, or 0.0006 to 0.0012 mass%.

[0017] The (C3) used in the present invention can be contained in an amount of about 0.0001 to 0.001% by mass based on the total amount of the composition. The upper or lower limit of the range of the content may be, for example, 0.0002, 0.0003, 0.0004, 0.0005, 0.0006, 0.0007, 0.0008, or 0.0009% by mass. For example, the range is more preferably 0.0002 to 0.0008% by mass, or 0.0003 to 0.0006% by mass.

[0018] The (C4) used in the present invention can be contained in an amount of about 0.0001 to 0.001% by mass based on the total amount of the composition. The upper or lower limit of the range of the content may be, for example, 0.0002, 0.0003, 0.0004, 0.0005, 0.0006, 0.0007, 0.0008, or 0.0009% by mass. For example, the range is more preferably 0.0002 to 0.0008% by mass, or 0.0003 to 0.0006% by mass.

[0019] Although not particularly limited, examples of the form of the topical skin composition of the present invention include ointments, creams, gels, lotions, emulsions, beauty essences, skin toners, face packs, etc., and can be used as cosmetics, quasi-drugs, or pharmaceuticals.

[0020] The topical skin composition of the present invention may further contain any known optional ingredient that can generally be incorporated into topical skin compositions, either alone or in combination of two or more kinds, within the scope of the invention not impairing the effects of the present invention.

[0021] In addition, the skin topical composition of the present invention may further contain known components used in skin topical compositions. Examples of such components include water, oils, surfactants, moisturizers, higher alcohols, sequestering agents, natural and synthetic polymers, water-soluble and oil-soluble polymers, UV shielding agents, various extracts, colorants such as organic dyes, preservatives, pigments, thickeners, pH adjusters, fragrances, cooling agents, antiperspirants, bactericides, skin activators, and various powders. The amount of these components can also be appropriately set based on information on the amount of these components to be contained in known skin topical compositions. There is no particular limit to the amount, but it may be, for example, about 1 to 99.9% by mass, or about 50 to 99.9% by mass.

[0022] The skin external composition of the present invention can be produced by a known method or a method easily conceived from a known method, for example, by appropriately mixing (A) retinoid, (B) phenolic antioxidant, (C1) 1,4-dioxacycloheptadecane-5,17-dione, (C2) benzyl salicylate, and (C3) 16-hydroxy-7-hexadecenoic acid lactone or (C4) 3a,6,6,9a-tetramethyl-dodecahydronaphtho[2,1-b]furan, and other known ingredients used in skin external compositions.

[0023] The present invention also preferably encompasses a method for suppressing the generation of offensive odors caused by a phenolic antioxidant when a composition for external use on the skin containing (A) a retinoid and (B) a phenolic antioxidant is left standing in a thermostatic chamber at 40° C. for one week by blending at least one of (C1) 1,4-dioxacycloheptadecane-5,17-dione, (C2) benzyl salicylate, and (C3) 16-hydroxy-7-hexadecenoic acid lactone or (C4) 3a,6,6,9a-tetramethyl-dodecahydronaphtho[2,1-b]furan.

[0024] It should be noted that in this specification, the term "comprising" includes "consisting essentially of" and "consisting of." EXAMPLES

[0025] The present invention will be described in detail below based on examples, but the present invention is not limited to these examples. Unless otherwise specified, the numerical values ​​in the tables represent mass %.

[0026] [Evaluation of topical skin composition] The test specimens of Examples 1 to 7 and Comparative Examples 1 to 4 were prepared in the usual manner with the blending amounts shown in Tables 1, 2, and 3, and were left to stand for one week in thermostatic chambers at -5°C and 40°C. After one week, four monitors evaluated the test specimens for suppression of sweet off-flavors and palatability.

[0027] [Evaluation criteria for sweet odor suppression] In this evaluation item, the extent to which the sweet unpleasant odor derived from the antioxidant in the test specimen kept at -40°C was suppressed compared to the test specimen (standard) kept at -5°C was judged and scored as follows. 4: No difference at all from the standard product 3: Almost no difference from the standard product 2: Slightly strange odor is detected compared to the standard product. 1: The odor is more pronounced than the standard product.

[0028] [Evaluation criteria for palatability] In this evaluation item, it was determined whether the scent generated when the test sample was applied had a desirable flavor as a composition for external use on the skin, and the result was scored as follows. 4: Very good, 3: Good, 2: Poor, 1: Very bad

[0029] The suppression of sweet off-flavors and the palatability were evaluated based on the average scores of each subject as shown below. 1: 4 points, 1: 3 points or more but less than 4 points, 1: 2 points or more but less than 3 points, ×: 1 point or more but less than 2 points

[0030] [Table 1]

[0031] [Table 2]

[0032] [Table 3]

[0033] Examples 1 to 6 in Table 2 showed good results in terms of palatability while suppressing the generation of sweet off-flavors. Furthermore, for Examples 1 and 3, the retinol amounts of the specimens left at -5°C and 40°C were measured, and the residual ratios of retinol in the specimens left at 40°C relative to the specimens left at -5°C were calculated, resulting in good residual ratios of 100% and 99.8%, respectively.

[0034] Formulation examples of the topical skin composition of the present invention are shown below. Note that the blending amount (%) of each formulation is by mass % unless otherwise specified.

[0035] [Prescription Example 1] TIFF0007605626000004.tif113115

[0036] [Prescription Example 2] TIFF0007605626000005.tif117115

[0037] [Prescription Example 3] TIFF0007605626000006.tif103115

Claims

[Claim 1] (A) retinol, (B) at least one of d-δ-tocopherol and dibutylhydroxytoluene, (C1) 1,4-dioxacycloheptadecane-5,17-dione, (C2) benzyl salicylate, and (C3) 16-hydroxy-7-hexadecenoic acid lactone or (C4) 3a,6,6,9a-tetramethyl-dodecahydronaphtho[2,1-b]furan; The (C1) is 0.001 to 0.09 mass %, The (C2) is 0.0005 to 0.05 mass %, and A composition for external use on skin containing 0.0002 to 0.002 mass % of at least one of (C3) or (C4).

Images